Imatinib resistant BCR‐ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study

the protocol. Acute mutiorgan failure is a common cause of death in adult sickle cell patients without Hepatitis-C (Perronne et al, 2002; Manci et al, 2003; Darbari et al, 2006). Cirrhosis with severe iron overload is often found on autopsy studies in adults with sickle cell disease. Close monitoring of the liver functions in patients on deferasirox is indicated. However, multiple studies have found that deferasirox protects against iron-induced hepatic injury as well as fulminant hepatitis (Al-Rousan et al, 2011; Deugnier et al, 2011; Sato et al, 2011). In summary, the acute multiorgan failure observed in this patient was secondary to the underlying sickle cell disease and the evidence does not indicate deferasirox as a causal agent.

[1]  Heather L. Mulder,et al.  Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[2]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[3]  C. Pui,et al.  Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Heerema,et al.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Kantarjian,et al.  Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors , 2008, Cancer.

[6]  J. Oldenburg,et al.  Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). , 2007, Blood.

[7]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[8]  D. Fabbro,et al.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia , 2004, Nature Genetics.

[9]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.